Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 3/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 3/20 | 0.35 |
| ▸ | CA1 | P00915 | 3/20 | 0.35 |
| ▸ | CA2 | P00918 | 3/20 | 0.35 |
| ▸ | CA4 | P22748 | 3/20 | 0.35 |
| ▸ | CA9 | Q16790 | 3/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18115167 | 0.84 | EPHX2 (0.38) | EPHX2CA12CA1CA2CA9 | |
| SCHEMBL4055087 | 0.82 | HDAC3 (0.33) | ESR2CA12CA1CA2CA4 | |
| SCHEMBL10103903 | 0.81 | HDAC3 (0.32) | HDAC8HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL2010262 | 0.80 | TSHR (0.52) | ESR2PTGS2CA12CA1CA2 | |
| SCHEMBL4055086 | 0.79 | MAPT (0.35) | CA12CA1CA2CA4CA9 | |
| SCHEMBL4055080 | 0.79 | CA12 (0.45) | CA12CA1CA2CA9 | |
| SCHEMBL134923 | 0.79 | EPHX2 (0.46) | EPHX2CA1CA2HDAC8HDAC3 | |
| SCHEMBL2009498 | 0.79 | TSHR (0.50) | ESR2PTGS2CA12CA1CA2 | |
| SCHEMBL2016061 | 0.79 | TSHR (0.50) | ESR2PTGS2CA12CA1CA2 | |
| SCHEMBL14152352 | 0.79 | TSHR (0.50) | ESR2PTGS2CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150376162-A1 | NSAIDs DERIVATIVES AND USES THEREOF | RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) | 2015-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376162-A1 | NSAIDs DERIVATIVES AND USES THEREOF | PTGES, PTGES3, PTGS1 | ESR2 3253/4885EPHX2 391/4885PTGS2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.